J Transl Med. 2006 Sep 4;4:38.

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.

Andersen MH, Soerensen RB, Becker JC, thor Straten P.

Abstract

Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8+ cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele in Asia. Consequently, this survivin-2B epitope is already a target in a clinical study in patients with advanced or recurrent colorectal cancer expressing survivin. However, the splice variant survivin-2B has been described to be pro-apoptotic, and is only expressed at low levels in most malignant tissues. Furthermore, survivin-2B expression are significantly decreased in later tumor stages and inversely correlated with tumor differentiation and invasion. Consequently, survivin is a more general vaccination candidate than the splice variant survivin-2B. Here, we on the basis of spontaneous immune responses in HLA-A24+ cancer patients describes that a HLA-A24-restricted survivin epitopes does indeed exist. Consequently, this epitope is an attractive target for the ongoing survivin-based peptide immunotherapy against cancer.

PMID:: 16948867; [PubMed]
PMCID: PMC1564416

Free PMC Article

Images from this publication.See all images (2) Free text

Publication Types

Editorial

LinkOut - more resources

Full Text Sources

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. [J Transl Med. 2009]
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J, Torigoe T, Hirohashi Y, Idenoue S, Miyazaki A, Yamaguchi A, Hiratsuka H, Sato N. J Transl Med. 2009 Jan 6; 7:1. Epub 2009 Jan 6.
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. [Clin Cancer Res. 2002]
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, et al. Clin Cancer Res. 2002 Jun; 8(6):1731-9.
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. [J Transl Med. 2004]
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, et al. J Transl Med. 2004 Jun 13; 2(1):19. Epub 2004 Jun 13.
[Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy]. [Gan To Kagaku Ryoho. 2004]
[Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
Tsuruma T, Torigoe T, Hata F, Furuhata T, Sato N, Hirata K. Gan To Kagaku Ryoho. 2004 Oct; 31(11):1634-6.
Review Survivin--a universal tumor antigen. [Histol Histopathol. 2002]
Review Survivin--a universal tumor antigen.
Andersen MH, thor SP. Histol Histopathol. 2002 Apr; 17(2):669-75.

See reviews... See all...

Cited by 3 PubMed Central articles

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. [J Transl Med. 2009]
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J, Torigoe T, Hirohashi Y, Idenoue S, Miyazaki A, Yamaguchi A, Hiratsuka H, Sato N. J Transl Med. 2009 Jan 6; 7:1. Epub 2009 Jan 6.
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. [J Transl Med. 2008]
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, et al. J Transl Med. 2008 May 10; 6:24. Epub 2008 May 10.
Review Cancer treatment: the combination of vaccination with other therapies. [Cancer Immunol Immunother. 2008]
Review Cancer treatment: the combination of vaccination with other therapies.
Andersen MH, Sørensen RB, Schrama D, Svane IM, Becker JC, Thor Straten P. Cancer Immunol Immunother. 2008 Nov; 57(11):1735-43. Epub 2008 Feb 20.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.
J Transl Med. 2006 Sep 4 ;4:38.

PubMed
Resident macrophages influence stem cell activity in the mammary gland.
Resident macrophages influence stem cell activity in the mammary gland.
Breast Cancer Res. 2009 ;11(4):R62. Epub 2009 Aug 26 .

PubMed
Downregulation of heat shock protein 70 protects rheumatoid arthritis fibroblast...
Downregulation of heat shock protein 70 protects rheumatoid arthritis fibroblast-like synoviocytes from nitric oxide-induced apoptosis.
Arthritis Res Ther. 2009 ;11(4):R130. Epub 2009 Aug 27 .

PubMed
Comprehensibility, reliability, validity, and responsiveness of the Thai version...
Comprehensibility, reliability, validity, and responsiveness of the Thai version of the Health Assessment Questionnaire in Thai patients with rheumatoid arthritis.
Arthritis Res Ther. 2009 ;11(4):R129. Epub 2009 Aug 27 .

PubMed
Seeking an ethical and legal way of procuring transplantable organs from the dyi...
Seeking an ethical and legal way of procuring transplantable organs from the dying without further attempts to redefine human death.
Philos Ethics Humanit Med. 2007 Jun 29 ;2:11.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.

Abstract

Publication Types

Publication Types

LinkOut - more resources

Full Text Sources

Libraries

Supplemental Content

Related citations

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information